Loading...

Neuren Pharmaceuticals Limited

NEU.AX•ASX
Healthcare
Biotechnology
A$17.33
A$0.40(2.36%)
empty-state-iconFinancials data is not available for this stockFinancials details for this stock are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

The company's financials show resilient growth, with revenue advancing from $14.55M in Q4 2022 to $24.33M in Q2 2024. Gross profit remained healthy with margins at 26% in Q2 2024 compared to 100% in Q4 2022. Operating income hit -$13.82M last quarter, sustaining a consistent -57% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $4.08M. Net income dropped to $8.02M, while earnings per share reached $0.06. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;